Author Archives: Ivana Magovčević-Liebisch

More than Just Words: Prioritizing Patient-Centered Drug Development
February 27, 2024

By Ivana Magovčević-Liebisch, CEO of Vigil Neuroscience, as part of the From The Trenches feature of LifeSciVC Patients and their care partners are at the center of our work in the life sciences industry – but at what point during

Leave a comment

An 18 Month Journey From Inception To IPO
November 16, 2022

By Ivana Magovčević-Liebisch PhD, JD, CEO of VIGIL NEUROSCIENCE, as part of the From The Trenches feature of LifeSciVC Compared to most industries, biotech life cycles are lengthy. From R&D and clinical development to regulatory approval, it takes an average

Leave a comment

You Can’t Do It Alone – The Importance of Riding the Same Bus
July 27, 2022

By Ivana Magovcevic-Liebisch, CEO of Vigil Neuroscience, as part of the From The Trenches feature of LifeSciVC From academic research, patent law, business development, to being a CEO, all my experiences have taught me two things. First, one cannot do

Leave a comment

Collaborating with Patient Advocacy Groups to Advance Rare Disease Awareness and Support
March 29, 2022

By Ivana Magovčević-Liebisch, CEO of Vigil Neuroscience, as part of the From The Trenches feature of LifeSciVC Over my many years in the biopharma industry, working across disease areas, including orphan indications, I have learned that to impact patients’ lives

Leave a comment